Rezolute Inc (NAS:RZLT)
$ 5.72 0.13 (2.33%) Market Cap: 229.57 Mil Enterprise Value: 151.92 Mil PE Ratio: 0 PB Ratio: 3.24 GF Score: 35/100

Rezolute Inc RZ358 Phase 3 Planning Update Call Transcript

Jun 27, 2023 / 08:30PM GMT
Release Date Price: $2.07 (-4.61%)
Operator

Hello and welcome to the Rezolute RZ358 Phase 3 planning update. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Nevan Elam, Chief Executive Officer and Founder. Please go ahead.

Nevan Elam
Rezolute, Inc. - CEO & Founder

Thank you and good afternoon. I appreciate all of you joining us today for an update on the status of our Phase 3 program for RZ358. I am joined by our Chief Medical Officer, Dr. Brian Roberts, as well as our Vice President of New Product Planning, Jeff Roeseler.

Also joining us is Dr. Paul Thornton, a distinguished pediatric endocrinologist and senior author on the hyperinsulinism management guidelines, which will soon be published. Needless to say, Dr. Thornton is a globally recognized expert in the management of patients with congenital HI.

Before we go any further, I would like to make a note that during the course of this call and the Q&A period, we may make forward-looking statements regarding future events or future clinical development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot